Bioengineered Protein Drugs Industry Outlook 2025-2029: Market Set to Cross $593.3 Billion Milestone

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Bioengineered Protein Drugs Market Size By 2025?
The market size for bioengineered protein drugs has seen significant growth in the past few years. It is projected to increase from $406.39 billion in 2024 to $435.17 billion in 2025, with a compound annual growth rate (CAGR) of 7.1%. This growth during the historic period can be traced back to advancements in disease understanding, regulatory approvals, an increase in chronic diseases prevalence, collaborations and partnerships, and expansion of the market.

How Big Is the Bioengineered Protein Drugs Market Size Expected to Grow by 2029?
The market for bioengineered protein drugs is forecasted to witness a significant surge in the coming years, escalating to a worth of "$593.3 billion by 2029", with a Compound Annual Growth Rate (CAGR) standing at 8.1%. The anticipated progression during this forecast period is attributable to factors such as the rise in personalized medicine, expanding therapeutic usage, burgeoning markets, concentration on rare diseases, and enhancement of healthcare infrastructure. The major emerging trends during this projected period encompass progress in protein engineering, a heightened emphasis on monoclonal antibodies, personalized medicine, and targeted therapy, the rise of next-generation biologics and streamlining of the manufacturing process.

View the full report here:
https://www.thebusinessresearchcompany.com/report/bioengineered-protein-drugs-global-market-report

Which Key Market Drivers Powering Bioengineered Protein Drugs Market Expansion and Growth?
The escalating prevalence of long-term illnesses is predicted to fuel the expansion of the bioengineered protein drug market. These chronic diseases are prolonged conditions requiring ongoing medical attention and often limiting individuals' normal physical activities. Bioengineered protein drugs are utilized in treating these chronic diseases, employing custom-designed protein treatments in fields like cancer therapy and regenerative medicine, leveraging a combination of strategies and logical approaches. For instance, the World Health Organization's 2022 Highlights reported in September 2022 that noncommunicable diseases (NCDs) or chronic diseases cause 41 million deaths annually, 74% of global deaths. This figure comprises 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Consequently, the rise in chronic illnesses is propelling the growth of the bioengineered protein drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10180&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Bioengineered Protein Drugs Market?
Leading firms in the bioengineered protein drug industry are utilizing the strategic partnerships model to supply vital bioengineered protein drugs to corporate entities and governmental bodies. The strategic partnerships model is a method where various firms exploit each other's capabilities and resources for collective benefit and progress. For instance, in June 2023, Future Fields, a biotechnology firm from Canada, collaborated with Jenthera Therapeutics, another Canadian biotech company that is focused on creating unique treatment methods for rare and complicated illnesses. The goal of this partnership is to create a new cancer-combatting protein by leveraging the EntoEngine platform of Future Fields for resource-efficient and sustainable large-scale production.

What Are the Emerging Segments in the Bioengineered Protein Drugs Market?
The bioengineered protein drugs market covered in this report is segmented -

1) By Drug Type: Recombinant Protein, Vaccine, Peptide Antibiotics, Therapeutic Enzymes, Other Drug Type
2) By Technology: Bioreactors, Fractionation, Genetically Modified Organisms, Genetic Engineering, Pharming, Cell Culture, Microbial Cell Fermentation, Other Technology
3) By Application: Autoimmune, Heart, Congenital, Infectious Diseases, Cancer, Diabetes, Arthritis, Other Application
4) By End User: Pharmaceutical, Contract Research Organizations, Research Institutes, Biotechnology Companies

Subsegments:
1) By Recombinant Protein: Monoclonal Antibodies, Hormones, Cytokines
2) By Vaccine: Recombinant Vaccines, DNA Vaccines
3) By Peptide Antibiotics: Lipopeptide Antibiotics, Glycopeptide Antibiotics
4) By Therapeutic Enzymes: Enzyme Replacement Therapies, Biosimilar Enzymes
5) By Other Drug Type: Fusion Proteins, Antibody-Drug Conjugates (ADCs)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10180&type=smp

Who Are the Global Leaders in the Bioengineered Protein Drugs Market?
Major companies operating in the bioengineered protein drugs market include Abbvie Inc., Amgen Inc., Astrazeneca PLC, Bayer HealthCare Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Novo Nordisk A/S, Sanofi S.A., Grifols S.A., Adma Biologics Inc., CSL Limited, Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, Merck & Co. Inc., Pfizer Inc., Biogen Inc., Bristol-Myers Squibb Company, Genentech Inc., Lonza Group AG, MedImmune LLC, Regeneron Pharmaceuticals Inc., Shire plc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shanghai United Cell Biotechnology Co. Ltd., Panacea Biotec Ltd.

Which are the Top Profitable Regional Markets for the Bioengineered Protein Drugs Industry?
North America was the largest region in the bioengineered protein drugs market in 2024. The regions covered in the bioengineered protein drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10180

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.